Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Notes Payables (2016 - 2025)

Heron Therapeutics' Notes Payables history spans 10 years, with the latest figure at $149.8 million for Q2 2025.

  • For Q2 2025, Notes Payables changed N/A year-over-year to $149.8 million; the TTM value through Jun 2025 reached $149.8 million, changed N/A, while the annual FY2020 figure was $7.1 million, 25.41% up from the prior year.
  • Notes Payables reached $149.8 million in Q2 2025 per HRTX's latest filing, up from $7.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $149.8 million in Q2 2025 to a low of $7.6 million in Q1 2021.